Theme trends in research related to retinal vein occlusion: a quantitative and co-word analysis

DOI: https://doi.org/10.21203/rs.2.9495/v1

Abstract

Background. This study focused on plotting knowledge structure and exploring research hotspots of retinal vein occlusion (RVO). Methods. In this study, research articles, with subject of RVO, were acquired from PubMed. Bibliographic Item Co-Occurrence Matrix Builder (BICOMB) was used for MeSH terms acquisition, evaluation and high-frequency MeSH term determination. Biclustering analysis and knowledge structure were conducted based on the MeSH term-source article matrix. RVO theme trends were illustrated with social network analysis (SNA), along with strategic diagrams. Results. A total of 3179 articles on RVO were retrieved, and the annual research output increased with time. USA ranked first with the most publications, with Retina as the most prolific journal in RVO research. MeSH terms were characterized into five different genres. As shown by the strategic diagram, the complications of RVO, the etiology of macular edema, as well as the therapeutic use of anti-VEGF, steroids and anti-inflammatory agents were well developed (Quadrant I). In contrast, epidemiology, metabolism and genetics related research on RVO were relatively immature (Quadrant III). Research on surgical treatments of vitrectomy, diagnostic methods and pathology of RVO were centralized but undeveloped (Quadrant IV). The SNA results was exhibited by the centrality chart, on which the node position was represented by the centrality values. Conclusions. By providing a bibliometric research, the overall RVO research trends could be revealed based on the five categories identified by this study. The mathematical bibliometric study could shed light on new perspectives for researchers.

BACKGROUND

Retinal vein occlusion (RVO) ranks the second most common cause of retinal vascular disease [1]. Central (CRVO), hemiretinal (HRVO) and branch (BRVO) vein occlusion are the three major categories of RVO based on the occlusion site. Patient symptoms may generally include, depending on the classification of RVO, blurry or missing vision, floating dots or lines, and defective visual field. The main complications of CRVO include the macular edema formation, neovascularization, neovascular glaucoma, and vitreous hemorrhage, while complications of BRVO depend more on the vessel occluded [2]. Academic journals have published a vast amount of papers in RVO related research over recent decades. In order to reduce the effort and time required for a traditional systematic literature review, we applied bibliometric methods to explore the research status in an RVO study.

Bibliometry is a computational analytical method, which is based on mathematical and statistical analysis of an article’s attributes, and it can be used to describe, assess and predict the current status and future development of science and technology [3]. Co-word and co-citation analyses are the common means employed in bibliometry analysis to demonstrate research trends. It is assumed that a collection of academic words from an article of interest can be used to outline this article. Based on this presumption, co-word analysis can be employed to assess the relationship of two academic words in an research literature. This study is focusing the assessment of RVO research trends with co-word analysis.

METHODS

Data Collection

Medical subject headings (MeSH) is a universal terminology used in academic publications to index and categorize biomedical information. In general, approximately ten to fifteen titles and subtitles are applied to index each published paper [4]. Co-word clustering analysis can be performed based on MeSH terms. In this study we select all journal articles in English from the PubMed database with the MeSH term “retinal vein occlusion”, and 3179 articles in total were identified and used in our analysis.

Data Extraction and Bibliographic Matrix Setup

Bibliographic Item Co-occurrence Matrix Builder (BICOMB), designed and built by Prof. Cui from China Medical University, was employed to examine the distribution features including publication time, nations, journals and researchers. In addition, BICOMB was also used to obtain the main MeSH terms/MeSH subheadings of these selected literatures [5]. The inventory, acquired from the PubMed database, was implemented for the generation of a term-source and co-occurrence matrix, and these matrices were further applied for subsequent bibliometric analysis.

Bi-clustering analysis of the high-frequency main MeSH terms/MeSH subheadings

Threshold value, T= (1+)/2, was used to evaluated the quantity of high-reoccurrence main MeSH terms/MeSH subheadings, and in this equation, “i” represents the quantity of key MeSH terms/MeSH subheadings with single appearance. RVO hot spots was explored with bi-clustering analysis which was based on the evaluation of high-reoccurrence MeSH terms and RVO-associated research articles. A binary matrix, with its rows built with high-reoccurrence key MeSH terms and its columns composed of source article, was developed. Then, the term-source article matrix was used to conduct co-occurrence double cluster analysis with gCLUTO software which can be retrieved from http://glaros.dtc.umn.edu/gkhome/cluto/gcluto. For hill diagram visualization, peaks are in accordance with the hotspots of the theme, which can be used to roughly estimate the clustering results. The different color appearing on the hill diagram represents different standard deviation (SD), the height of the hill is proportional to the similarity in intra-class and the hill volume is correlated with the quantity of MeSH terms. For dendrogram, high-reoccurrence key MeSH terms were displayed as the row labels and the PubMed Unique Identifiers (PMIDs) of the source publications were listed as the column names.

Strategic diagram analysis

The strategic diagram analysis is based on themes of centrality and density. Centrality is represented by the external cohesion index, indicating the them position in the framework, and density is illustrated by the internal cohesion index, reflecting the progression of the themes. With X-axis representing centrality and Y-axis illustrating density, four quadrants were developed. Based on the biclustering assessment, different clusters generated were distributed in different quadrants of this strategic diagram generated by Graph.

Social network analysis

SNA network was developed using Ucinet 6.0 (Analytic Technologies Co., Lexington, KY, USA) software according to the high-reoccurrence key MeSH terms/MeSH subheadings co-occurrence matrix. A two-dimensional map, for visualization, was generated with the key MeSH terms/MeSH subheadings using NetDraw 2.084 software. On this map, the key MeSH terms/MeSH subheadings were shown as the nodes and the frequency of their co-occurrence was displayed as the links. Furthermore, closeness, betweenness and degree centralities were employed to examine the location of the key MeSH terms/MeSH subheadings, in order to obtain in-depth understanding of RVO network organization.

RESULTS

Distribution characteristics of relevant literatures

With the searching criteria described above, 3179 publications in total were included in this study. As displayed in Fig.1A, research articles published yearly in the RVO field has gradually increased from 90 in 2004, to over 200 in 2015. Among all the first authors involved in this topic, Noma H ranked first by publishing 52 articles (Fig.1B). As for the amount of RVO research output, the United States ranked first with 1,544 publications, making up almost 50% of the research in this specific area (Fig.1C). Among the top 10 most productive journals displayed on Fig.1D, Retina, American Journal of Ophthalmology and Ophthalmology are listed as the top three, and these identified top journals are considered to be the principal journals in RVO field.

Research hot spots identification with MeSH term clusters

According to Table 1, 73 MeSH terms, representing 57.6% all MeSH terms, were identified as the high-reoccurrence MeSH terms. These 73 high-reoccurrence MeSH terms could be used to reveal the hot spots of studies in the field of RVO.

The visualization of the key MeSH terms/MeSH subheadings using the hill diagram and dendrogram, based on biclustering analysis, are presented on Fig. 2. According to the evaluation of the MeSH terms, RVO research hot spots were classified into five categories (Table 2). These categories mainly include the following content: (1) Research related to the epidemiology and metabolism of RVO (cluster 0); (2) Studies on the complications of RVO, and the etiology of macular edema; the therapeutic use of monoclonal/humanized antibodies, glucocorticoids, triamcinolone acetonide, dexamethasone and anti-inflammatory agents (cluster 1); (3) Surgical treatment of vitrectomy (cluster 2); (4) Genetics related research on RVO (cluster 3); and (5) Pathology of RVO and diagnostic methods including fundus fluorescein angiography (FFA) and optical coherence tomography (OCT) (cluster 4). The key research topics of RVO could be revealed by the above mentioned five clusters.

Table 2 Cluster analysis of high-frequency major MeSH terms/MeSH subheadings of retinal vein occlusion

Cluster

Number of MeSH terms*

Cluster analysis

0

41,18,46,39,40,44,38,65,20

1.Retinal vein occlusion metabolism and epidemiology

2.Aqueous humor, macular edema, vitreous body and iris metabolism

1

29,3,53,37,13,9,10,4,2,1,28,26,52,55,19,64

1.Retinal vein occlusion complications and macular edema etiology 2.Retinal vein occlusion and macular edema drug therapy

2

70,61,57,16,59,32,31,14,6,54,33,45,60,69

1.Retinal and choroid neovascularization 2.Ophthalmologic Surgical Procedures

3

66,51,22,73,48,23,43,34,42,24,5,50,25

1.Retinal vein occlusion etiology and genetics: point mutation, factor V and NADPH2

2.Retinal vein occlusion complications: hyperhomocysteinemia, antiphospholipid syndrome and vision disorders

3.Retinal artery occlusion etiology and complications

4

68,71,27,7,36,49,17,63,56,72,67,58,8,62,11,21,15,35,47,14,30

1.Retina and vessels physiology and physiopathology

2.Pathology of retinal vein occlusion

3.Retinal diseases diagnosis and methods

*Represents the serial number of high-frequency major MeSH terms/MeSH subheadings shown in Table S1.

Theme trends of RVO

Themes in Quadrant I with the features of intensive centrality and density are considered as the motor themes. Quadrant II, located at the upper-left quadrant, containing with specialized themes with low centrality but intensive density. The bottom-left quadrant, Quadrant III, includes themes with inadequate density and centrality, and the themes in the quadrant are generally regarded to be either emerging or fading. The bottom-right quadrant, Quadrant IV, holds themes with intensive centrality but inadequate density, indicating themes without internal maturation. These themes were distributed in the quadrants of the strategic diagram with spherical shapes and their location was based on the value of density and centrality indicating the internal and external correlation, respectively (Fig. 3A). As shown in Fig. 3B, Cluster 1 includes studies on the complications of RVO, the etiology of macular edema, and the therapeutic use of monoclonal/humanized antibodies, steroids and anti-inflammatory agents and it is assigned to Quadrant I, indicating their pivotal position with significant centrality and density. Cluster 0 and 3 are assigned to Quadrant III, consisting of studies on the metabolism, epidemiology and genetics of RVO that are still immature, especially in the peripheral regions of current studies. Whereas, Cluster 2 and 4 are located in Quadrant IV, representing that studies that include ophthalmologic surgical procedures, diagnostic methods and the pathology of RVO are undeveloped while in the central position.

Social network analysis of RVO

SNA network organization was defined by centrality parameters including degree, betweenness and closeness centralities (Table 3A&3B).

The top ten MeSH terms with high-reoccurrence exhibits higher degree centralities comparing to the average of 220.219±346.829. “Macular edema/drug therapy” is listed as a MeSH term with the highest reoccurrence rate showing the greatest degree centrality as 1,894. “Retinal vein occlusion/complications” and “Retinal vein occlusion/diagnosis” are listed with the highest betweenness centrality with the value of 204.59 and 177.057, respectively, and indicating most intensive mediating roles in the network. Whereas, with the average betweenness centrality determined as 25.534±42.030 (Table 3B), MeSH terms “Dexamethasone/ therapeutic use” “VEGFA/ antagonists & inhibitors” and “Ranibizumab/ therapeutic use” show relative lower betweenness centrality values as 8.775, 19.518 and 16.643, respectively. However, these three MeSH terms show higher degree centralities values as 442, 279 and 246, respectively, comparing with the degree centrality mean value of 220.219. Meanwhile, MeSH terms “Retinal vein occlusion/complications” have the top closeness centrality of 66.

To better understand this, the betweenness centrality was used to develop the SNA. As shown in Fig. 4, the betweenness centrality is represented by the node size and co-occurrence frequency is displayed by line width.

DISCUSSION

Based on the assumptions that literature content can be represented by selected MeSH terms, research status of a specific theme can be revealed by an aggregation of MeSH terms. Statistical evaluation using BICOMB software indicates that the overall trend of research articles on “retinal vein occlusion” [MeSH] is featured as an increase peaked in 2015. Furthermore, US and England are identified as the two countries with the most publications on RVO, and one of the reasons for this could be that their native language is English.

With the focus on investigating the structures of RVO knowledge systemically, co-word evaluation, biclustering examination, strategic diagram and bibliometric SNA were included in this study. Clusters were formed and identified with MeSh terms that are associated closely through the co-word and biclustering evaluation. Cluster 1 was identified to be associated with studies on the complications of RVO, the etiology of macular edema and the therapeutic use of monoclonal/humanized antibodies, corticosteroids and anti-inflammatory agents. Age and systemic disorders were identified as the top two risk factors for RVO. RVO prevalence increases significantly with age but does not differ by gender [6], probably due to atherosclerosis. Systemic diseases such as hypertension, diabetes mellitus, hyperlipidemia, thrombophilia, hypercoagulation and inflammatory diseases are strongly associated with RVO [7]. RVO patients may suffer a variety of complications, the most significant of which is macular edema. Other serious complications include vascularization of the retina and optic disc (which can result in vitreous hemorrhage), retinal detachment, neovascular glaucoma and even blindness [8]. Cystoid macular edema (CME), which is caused by capillary congestion, may result in the metamorphopsia and even loss of visual acuity. A multicenter, randomized clinical trial examined the efficacy and safety of 1-mg and 4-mg doses of intravitreal triamcinolone acetonide (IVTA) in comparison with standard grid photocoagulation for BRVO. Investigators reported similar improvement in OCT thickness over 1-year observation in all groups. In terms of complications, cataract progression rate was higher in the 4mg IVTA group, thus IVTA is less commonly used than anti-VEGF therapy [9]. VEGF is an inflammatory cytokine that promotes vascular permeability and is upregulated in eyes with vein occlusion [10]. Ranibizumab and bevacizumab are humanized monoclonal antibodies that are active against the VEGF-A molecule. Different clinical trials on anti-VEGF injections suggest that intraocular anti-VEGF injection can significantly improve vision acuity in eyes with BRVO [11]. These topics in Cluster 1, positioned in Quadrant I, are the centralized and matured hotspots in the RVO field.

Cluster 0 is associated with research on epidemiology and the metabolism of RVO. The prevalence of RVO has been reported to range between 0.4% and 4.6%. Of the two main types of RVO, BRVO is four to six times more prevalent than CRVO [12]. The balance between inflammatory cytokines and angiogenesis in eye fluid is disturbed in patients with RVO. Exposure of endothelial cells to proinflammatory cytokines can cause oxidative stress and apoptosis, aggravating leukocyte efflux and thrombosis. Significantly increased concentrations of IL-1α, -6, and -8; IP-10; and PDGF-AA were observed in RVO patients when compared to control patients [10]. Macular edema secondary to RVO is associated with increased levels of VEGF in the aqueous humor. Therefore, the management of macular edema secondary to RVO, especially in the presence of capillary con-perfusion areas, should aim at reducing ocular VEGF concentration [13]. Cluster 3 relates to genetic studies on RVO. Thrombophilic diseases like factor V Leiden mutation, hyperhomocysteinemia and anticardiolipin antibodies increase the risk of RVO [14]. Proteomic studies suggest that RVO is associated with the remodeling of the extracellular matrix and adhesion processes. However, many areas of proteome changes in RVO remain unstudied. Future studies may address long-lasting retinal changes following intervention with anti-VEGF agents, such as dexamethasone intravitreal implants [15]. These two clusters, assigned to Quadrant III, represents research hotspots which are marginal and immature, and future research on these topics is suggested.

Cluster 2 relates to the surgical treatment of RVO. Macular grid laser photocoagulation is an effective treatment for macular edema in patients with BRVO. Other treatment options for reducing edema are intravitreal steroids, anti-VEGF drugs and vitrectomy. It has also been reported that vitrectomy is effective for reducing macular edema and improving visual acuity in patients with BRVO. Vitrectomy probably reduces macular edema by allowing oxygenated fluid to circulate in the vitreous cavity, improving perifoveal microcirculation, and increasing the clearance of VEGF in the vitreous cavity. A five-year follow-up of vitrectomy for macular edema associated with BRVO revealed that vitrectomy may evade the risks associated with repeated injections; however, the incidences of postoperative RD were higher than that of intravitreal injections [16]. Cluster 4 is associated with the pathophysiology and RVO diagnosis. In RVO patients, signs of oxidative stress, such as enhanced plasma lipid peroxidation and decreased antioxidant activity of paraoxonase, have been reported [17]. M. Becatti, et al. compared ROS production and membrane lipid peroxidation in RVO patients and control subjects. The results indicated that erythrocyte oxidative stress is an essential factor in the pathogenesis of RVO disease [18]. Suzuki et al. reported that anti-VEGF therapy might improve retinal deep ischemia in the retinal deep layer of patients with RVO [19]. In clinical practice, treatment decisions commonly depend on OCT measurements. OCT provides high-resolution imaging of the fovea and is helpful in detecting the presence of macular edema, vitreoretinal interface changes, neurosensory retinal detachment and subretinal fluid. Optical coherence tomography angiography (OCTA) can evaluate the retinal hemodynamics in patients with RVO. FFA is able to detect peripheral capillary nonperfusion, macular ischemia, and subtle neovascularization. Eyes with more capillary nonperfusion have a greater risk of ocular neovascularization. FFA may also help to distinguish collateralization from neovascularization, since the former does not leak fluorescein, whereas the latter does [20]. These two clusters are assigned to Quadrant IV and include immature but centralized research topics.

According to the RNA analytical outcome, MeSH terms ranked the top three are “Macular edema/drug therapy”, “Antibody, monoclonal, humanized/therapeutic use” and “Retinal vein occlusion/drug therapy”, showing high degree centralities. These MeSH terms are with the most directly links with other components, pioneering the progress of the RVO research. With regard to the betweenness centrality analysis, “Retinal vein occlusion/complications”, “Retinal vein occlusion/diagnosis” and “Retinal vein occlusion/physiopathology” are identified to be located at the network center, representing the key components with the highest influence in the determination of other components’ co-occurrence. “Retinal vein/pathology” and “Retina/pathology” are among the top ten MeSH terms with betweenness centrality; however, these two components are located in the IV quadrant and are not included in the MeSH terms listed with the top ten high-reoccurrence. This demonstrates that although these two components are important in the network stability, but the research on this topic is not well developed.

CONCLUSIONS

In summary, the structure and maturity of an identified field can be evaluated and revealed with clustering analysis and strategic diagrams. SNA has the advantage of identifying the associations among the high-reoccurrence MeSH terms. The key foci on current research include drug therapy and pathogenesis alterations, and genetics-based studies are the novel developing areas. The purpose of this bibliometric study is to shed some light on research topic selection for researchers in the RVO field. However, potential methodological limitations should also be evaluated by researchers. First, the publications extracted from PubMed may not be comprehensive enough to cover all of the topics in RVO literature. Secondly, research article and journal qualities are not consistent, with articles from top tier journals showing significant impact in comparison with those of little influence from inferior journals. Thus, the contribution should have not be considered the same in the knowledge structure during analysis. Finally but not lastly, high-reoccurrence MeSH terms were used for the co-word analysis and novel research topics may be excluded from the analysis due to low-reoccurrence, which may introduce bias during the analysis. Due to the above potential limitations, future analyses should take the newly emerging topics and multiple databases into consideration.

DECLARATIONS

Acknowledgements

The authors would like to thank the editor and all reviewers for their valuable comments to improve the quality of this paper.

Funding

This work was supported by Norman Bethune-Lumitin Young and middle-aged ophthalmic research fund (No. BJ-LM2015009L). The Funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Availability of data and materials

The datasets included in this study are available in the PubMed database.

Author contributions

FL conceived the rearch, finished the manuscript and reviewed the final version. XC and MZ extracted data and prepared figures/ tables. All authors have read and approved the manuscript.

Ethics approval and consent to participate

Not applicable

Consent for publication

Not applicable

Competing interests

No competing interests.

Abbreviations

RVO: retinal vein occlusion; CRVO: central retinal vein occlusion; HRVO: hemiretinal retinal vein occlusion; BRVO: branch retinal vein occlusion; BICOMB: Bibliographic item co-occurrence matrix builder; SNA: social network analysis; MeSH: Medical subject headings; FFA: fundus fluorescein angiography; OCT: optical coherence tomography; OCTA: optical coherence tomography angiography; CME: cystoid macular edema; IVTA: intravitreal triamcinolone acetonide.

REFERENCE

1. Coscas G, Loewenstein A, Augustin A, Bandello F, Battaglia Parodi M, Lanzetta P, Mones J, de Smet M, Soubrane G, Staurenghi G: Management of retinal vein occlusion--consensus document. Ophthalmologica Journal international d'ophtalmologie International journal of ophthalmology Zeitschrift fur Augenheilkunde 2011, 226(1):4-28.

2. Baseline and early natural history report. The Central Vein Occlusion Study. Archives of ophthalmology 1993, 111(8):1087-1095.

3. Zou X, Yue WL, Vu HL: Visualization and analysis of mapping knowledge domain of road safety studies. Accident; analysis and prevention 2018, 118:131-145.

4. Zhao F, Shi B, Liu R, Zhou W, Shi D, Zhang J: Theme trends and knowledge structure on choroidal neovascularization: a quantitative and co-word analysis. BMC ophthalmology 2018, 18(1):86.

5. Li F, Li M, Guan P, Ma S, Cui L: Mapping publication trends and identifying hot spots of research on Internet health information seeking behavior: a quantitative and co-word biclustering analysis. Journal of medical Internet research 2015, 17(3):e81.

6. Rogers S, McIntosh RL, Cheung N, Lim L, Wang JJ, Mitchell P, Kowalski JW, Nguyen H, Wong TY, International Eye Disease C: The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology 2010, 117(2):313-319 e311.

7. Jaulim A, Ahmed B, Khanam T, Chatziralli IP: Branch retinal vein occlusion: epidemiology, pathogenesis, risk factors, clinical features, diagnosis, and complications. An update of the literature. Retina 2013, 33(5):901-910.

8. Rehak M, Wiedemann P: Retinal vein thrombosis: pathogenesis and management. Journal of thrombosis and haemostasis : JTH 2010, 8(9):1886-1894.

9. Scott IU, Ip MS, VanVeldhuisen PC, Oden NL, Blodi BA, Fisher M, Chan CK, Gonzalez VH, Singerman LJ, Tolentino M et al: A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular Edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6. Archives of ophthalmology 2009, 127(9):1115-1128.

10. Funk M, Kriechbaum K, Prager F, Benesch T, Georgopoulos M, Zlabinger GJ, Schmidt-Erfurth U: Intraocular concentrations of growth factors and cytokines in retinal vein occlusion and the effect of therapy with bevacizumab. Investigative ophthalmology & visual science 2009, 50(3):1025-1032.

11. Gerding H: Results of a Meta-Analysis on Intravitreal anti-VEGF Treatment of Macular Oedema Secondary to Branch Retinal Vein Occlusion (BRVO). Klinische Monatsblatter fur Augenheilkunde 2017, 234(4):551-555.

12. Kolar P: Risk factors for central and branch retinal vein occlusion: a meta-analysis of published clinical data. Journal of ophthalmology 2014, 2014:724780.

13. Machalinska A, Mozolewska-Piotrowska K, Czepita M, Spoz W, Dzieciolowska M, Kubasik-Kladna K, Szmatloch K, Lubinski W, Safranow K, Pius-Sadowska E: Aqueous levels of VEGF correlate with retinal non-perfusion areas in patients with diabetic macular edema and macular edema secondary to central retinal vein occlusion. Klinika oczna 2016, 117(4):225-229.

14. Nema N, Verma S, Kumar R: Investigation of methylenetetrahydrofolate reductase C677T and factor V Leiden mutation as a genetic marker for retinal vein occlusion. Taiwan journal of ophthalmology 2018, 8(2):99-103.

15. Cehofski LJ, Honore B, Vorum H: A Review: Proteomics in Retinal Artery Occlusion, Retinal Vein Occlusion, Diabetic Retinopathy and Acquired Macular Disorders. International journal of molecular sciences 2017, 18(5).

16. Nishida A, Kojima H, Kameda T, Mandai M, Kurimoto Y: Five-year outcomes of pars plana vitrectomy for macular edema associated with branch retinal vein occlusion. Clinical ophthalmology 2017, 11:369-375.

17. Angayarkanni N, Barathi S, Seethalakshmi T, Punitham R, Sivaramakrishna R, Suganeswari G, Tarun S: Serum PON1 arylesterase activity in relation to hyperhomocysteinaemia and oxidative stress in young adult central retinal venous occlusion patients. Eye 2008, 22(7):969-974.

18. Becatti M, Marcucci R, Gori AM, Mannini L, Grifoni E, Alessandrello Liotta A, Sodi A, Tartaro R, Taddei N, Rizzo S et al: Erythrocyte oxidative stress is associated with cell deformability in patients with retinal vein occlusion. Journal of thrombosis and haemostasis : JTH 2016, 14(11):2287-2297.

19. Suzuki N, Hirano Y, Tomiyasu T, Esaki Y, Uemura A, Yasukawa T, Yoshida M, Ogura Y: Retinal Hemodynamics Seen on Optical Coherence Tomography Angiography Before and After Treatment of Retinal Vein Occlusion. Investigative ophthalmology & visual science 2016, 57(13):5681-5687.

20. Ip M, Hendrick A: Retinal Vein Occlusion Review. Asia-Pacific journal of ophthalmology 2018, 7(1):40-45.

Tables 1 & 3

Table 1 High-frequency MeSH terms/MeSH subheadings from the included papers on retinal vein occlusion

Rank

Major MeSH terms/ MeSH subheadings

Frequency

Proportion of frequency (%)

Cumulative percentage (%)

1

Macular Edema / drug therapy

603

4.8818

4.8818

2

Antibodies, Monoclonal, Humanized / therapeutic use

594

4.8089

9.6907

3

Retinal Vein Occlusion / complications

548

4.4365

14.1273

4

Retinal Vein Occlusion / drug therapy

510

4.1289

18.2562

5

Retinal Vein Occlusion / etiology

391

3.1655

21.4216

6

Retinal Vein Occlusion / surgery

367

2.9712

24.3928

7

Retinal Vein Occlusion / physiopathology

290

2.3478

26.7406

8

Retinal Vein Occlusion / diagnosis

276

2.2345

28.9751

9

Glucocorticoids / therapeutic use

242

1.9592

30.9343

10

Triamcinolone Acetonide / therapeutic use

170

1.3763

32.3106

11

Retinal Vein / pathology

153

1.2387

33.5492

12

Visual Acuity / physiology

139

1.1253

34.6745

13

Dexamethasone / therapeutic use

136

1.1010

35.7756

14

Laser Coagulation / methods

125

1.0120

36.7876

15

Tomography, Optical Coherence / methods

115

0.9310

37.7186

16

Vitrectomy / methods

98

0.7934

38.5120

17

Retinal Vein Occlusion / pathology

88

0.7124

39.2244

18

Retinal Vein Occlusion / metabolism

84

0.6801

39.9045

19

VEGFA / antagonists & inhibitors

83

0.6720

40.5764

20

Retinal Vein Occlusion / epidemiology

82

0.6639

41.2403

21

Fluorescein Angiography / methods

80

0.6477

41.8880

22

Retinal Vein Occlusion / genetics

78

0.6315

42.5194

23

Retinal Vein Occlusion / blood

78

0.6315

43.1509

24

Retinal Artery Occlusion / etiology

75

0.6072

43.7581

25

Retinal Vein Occlusion / chemically induced

69

0.5586

44.3167

26

Ranibizumab / therapeutic use

66

0.5343

44.8510

27

Macular Edema / physiopathology

65

0.5262

45.3773

28

Bevacizumab / therapeutic use

64

0.5181

45.8954

29

Macular Edema / etiology

63

0.5100

46.4054

30

Retina / pathology

61

0.4938

46.8993

31

Retinal Vein / surgery

57

0.4615

47.3608

32

Choroid / blood supply

57

0.4615

47.8222

33

Optic Nerve / surgery

56

0.4534

48.2756

34

Retinal Artery Occlusion / complications

45

0.3643

48.6399

35

Macular Edema / diagnosis

44

0.3562

48.9961

36

Electroretinography

40

0.3238

49.3199

37

Anti-Inflammatory Agents / therapeutic use

38

0.3076

49.6276

38

Tissue Plasminogen Activator / therapeutic use

37

0.2995

49.9271

39

Vitreous Body / metabolism

36

0.2915

50.2186

40

VEGFA / metabolism

36

0.2915

50.5100

41

Aqueous Humor / metabolism

35

0.2834

50.7934

42

Vision Disorders / etiology

35

0.2834

51.0767

43

Hyperhomocysteinemia / complications

35

0.2834

51.3601

44

Iris / blood supply

33

0.2672

51.6273

45

Decompression, Surgical / methods

33

0.2672

51.8944

46

Macular Edema / metabolism

33

0.2672

52.1616

47

Macula Lutea / pathology

31

0.2510

52.4126

48

Homocysteine / blood

31

0.2510

52.6635

49

Retina / physiopathology

30

0.2429

52.9064

50

Antiphospholipid Syndrome / complications

29

0.2348

53.1412

51

Factor V / genetics

28

0.2267

53.3679

52

Recombinant Fusion Proteins / therapeutic use

28

0.2267

53.5946

53

Glucocorticoids / adverse effects

27

0.2186

53.8131

54

Optic Disk / surgery

27

0.2186

54.0317

55

VEGFR / therapeutic use

27

0.2186

54.2503

56

Retinal Vessels / physiopathology

27

0.2186

54.4689

57

Retinal Detachment / etiology

26

0.2105

54.6794

58

Retinal Artery Occlusion / diagnosis

26

0.2105

54.8899

59

Retinal Vein / physiopathology

25

0.2024

55.0923

60

Ophthalmologic Surgical Procedures

25

0.2024

55.2947

61

Optic Disk / blood supply

24

0.1943

55.4890

62

Ischemia / diagnosis

24

0.1943

55.6833

63

Optic Disk / pathology

23

0.1862

55.8695

64

Diabetic Retinopathy / drug therapy

23

0.1862

56.0557

65

Fibrinolytic Agents / therapeutic use

23

0.1862

56.2419

66

Point Mutation

23

0.1862

56.4281

67

Retinal Diseases / diagnosis

22

0.1781

56.6062

68

Retina / blood supply

22

0.1781

56.7843

69

Retinal Vein / physiology

21

0.1700

56.9543

70

Retinal Neovascularization / etiology

21

0.1700

57.1244

71

Retinal Vessels / physiology

21

0.1700

57.2944

72

Vitreous Body / pathology

21

0.1700

57.4644

73

NADPH2 / genetics

21

0.1700

57.6344

VEGFA: Vascular Endothelial Growth Factor A; VEGFR: Vascular Endothelial Growth Factor Receptors; NADPH2: Methylenetetrahydrofolate Reductase

Table 3A Individual centrality of retinal vein occlusion research

Rank

Major MeSH terms/ MeSH subheadings

Degree

betweenness

Closeness

1

Macular Edema / drug therapy

1894.000

80.059

60.000

2

Antibodies, Monoclonal, Humanized / therapeutic use

1619.000

94.753

62.000

3

Retinal Vein Occlusion / complications

1013.000

204.59

66.000

4

Retinal Vein Occlusion / drug therapy

1369.000

133.827

64.000

5

Retinal Vein Occlusion / etiology

282.000

124.109

57.500

6

Retinal Vein Occlusion / surgery

684.000

94.747

62.000

7

Retinal Vein Occlusion / physiopathology

364.000

136.091

61.500

8

Retinal Vein Occlusion / diagnosis

442.000

177.057

62.500

9

Glucocorticoids / therapeutic use

801.000

42.612

57.000

10

Triamcinolone Acetonide / therapeutic use

557.000

40.277

56.500

11

Retinal Vein / pathology

296.000

83.365

57.500

12

Visual Acuity / physiology

423.000

35.901

56.000

13

Dexamethasone / therapeutic use

442.000

8.775

49.500

14

Laser Coagulation / methods

352.000

34.94

55.500

15

Tomography, Optical Coherence / methods

351.000

31.979

56.000

16

Vitrectomy / methods

239.000

35.908

55.000

17

Retinal Vein Occlusion / pathology

96.000

14.796

51.000

18

Retinal Vein Occlusion / metabolism

144.000

38.806

49.500

19

VEGFA / antagonists & inhibitors

279.000

19.518

51.000

20

Retinal Vein Occlusion / epidemiology

60.000

19.197

49.000

21

Fluorescein Angiography / methods

219.000

19.706

53.500

22

Retinal Vein Occlusion / genetics

73.000

12.664

43.833

23

Retinal Vein Occlusion / blood

39.000

2.870

41.000

24

Retinal Artery Occlusion / etiology

114.000

22.276

48.500

25

Retinal Vein Occlusion / chemically induced

17.000

1.772

41.833

26

Ranibizumab / therapeutic use

246.000

16.643

50.500

27

Macular Edema / physiopathology

138.000

11.415

50.167

28

Bevacizumab / therapeutic use

225.000

25.401

52.500

29

Macular Edema / etiology

172.000

19.417

53.000

30

Retina / pathology

173.000

43.715

57.000

31

Retinal Vein / surgery

132.000

6.812

45.833

32

Choroid / blood supply

128.000

21.483

50.500

33

Optic Nerve / surgery

134.000

16.381

50.000

34

Retinal Artery Occlusion / complications

67.000

5.589

44.000

35

Macular Edema / diagnosis

125.000

5.003

47.500

36

Electroretinography

70.000

3.634

46.500

37

Anti-Inflammatory Agents / therapeutic use

128.000

2.351

44.167

38

Tissue Plasminogen Activator / therapeutic use

67.000

2.167

43.000

39

Vitreous Body / metabolism

90.000

3.881

45.000

40

VEGFA / metabolism

106.000

2.239

45.500

41

Aqueous Humor / metabolism

90.000

4.245

45.500

42

Vision Disorders / etiology

60.000

4.384

46.000

43

Hyperhomocysteinemia / complications

65.000

5.171

41.833

44

Iris / blood supply

45.000

5.346

45.500

45

Decompression, Surgical / methods

84.000

3.642

45.000

46

Macular Edema / metabolism

87.000

3.332

43.833

47

Macula Lutea / pathology

88.000

4.964

47.000

48

Homocysteine / blood

55.000

3.908

40.833

49

Retina / physiopathology

96.000

2.991

47.000

50

Antiphospholipid Syndrome / complications

32.000

0.255

39.167

51

Factor V / genetics

41.000

0.283

37.167

52

Recombinant Fusion Proteins / therapeutic use

129.000

0.174

39.833

53

Glucocorticoids / adverse effects

31.000

0.640

40.500

54

Optic Disk / surgery

66.000

4.719

44.000

55

VEGFR / therapeutic use

126.000

0.174

39.833

56

Retinal Vessels / physiopathology

53.000

8.830

47.500

57

Retinal Detachment / etiology

46.000

4.854

45.000

58

Retinal Artery Occlusion / diagnosis

57.000

3.530

45.000

59

Retinal Vein / physiopathology

38.000

0.350

42.000

60

Ophthalmologic Surgical Procedures

57.000

1.365

41.667

61

Optic Disk / blood supply

44.000

4.631

45.500

62

Ischemia / diagnosis

80.000

10.025

47.000

63

Optic Disk / pathology

35.000

1.299

42.333

64

Diabetic Retinopathy / drug therapy

74.000

3.540

41.667

65

Fibrinolytic Agents / therapeutic use

35.000

0.471

39.667

66

Point Mutation

37.000

1.600

39.333

67

Retinal Diseases / diagnosis

41.000

0.983

42.167

68

Retina / blood supply

23.000

0.000

35.333

69

Retinal Vein / physiology

39.000

2.148

41.833

70

Retinal Neovascularization / etiology

30.000

1.697

40.667

71

Retinal Vessels / physiology

47.000

1.931

43.000

72

Vitreous Body / pathology

31.000

1.771

42.833

73

NADPH2 / genetics

44.000

1.017

38.000

VEGFA: Vascular Endothelial Growth Factor A; VEGFR: Vascular Endothelial Growth Factor Receptors; NAPDH2: Methylenetetrahydrofolate Reductase

Table 3B Descriptive statistics for centrality measure about retinal vein occlusion

Centralization

Mean ± SD

Min

Max

Network centralization

Degree

220.219 ± 346.829

17.000

1894.000

6.044%

Betweenness

25.534 ± 42.030

0.000

204.590

7.140%

Closeness

47.895 ± 7.168

35.333

66.000

51.35%